| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VPH.2017.10.003 |
| P698 | PubMed publication ID | 29051088 |
| P50 | author | Franco Dallegri | Q57055807 |
| Alessandra Vecchiè | Q87596973 | ||
| Matteo Casula | Q99208206 | ||
| Aldo Bonaventura | Q47626964 | ||
| Federico Carbone | Q48174177 | ||
| Luca Liberale | Q41112874 | ||
| Fabrizio Montecucco | Q41112895 | ||
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| Structural recognition and functional activation of FcγR by innate pentraxins | Q27652907 | ||
| The Protective Effect against Extracellular Histones Afforded by Long-Pentraxin PTX3 as a Regulator of NETs | Q28080336 | ||
| Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition | Q28115835 | ||
| Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis | Q28118263 | ||
| M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules | Q28118843 | ||
| PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages | Q28588062 | ||
| Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation | Q29147380 | ||
| Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells | Q30367803 | ||
| Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts | Q33377856 | ||
| Whole blood transcriptomics in cardiac surgery identifies a gene regulatory network connecting ischemia reperfusion with systemic inflammation | Q33737507 | ||
| Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis | Q33748025 | ||
| Pentraxin-3 and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study | Q33805985 | ||
| The relationship between IL-10 levels and cardiovascular events in patients with CKD. | Q33835698 | ||
| C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction | Q33883883 | ||
| PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans | Q33912738 | ||
| Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation | Q33944773 | ||
| Human pentraxin 3 binds to the complement regulator c4b-binding protein. | Q34018825 | ||
| Pentraxin 3 as a Novel Marker Predicting Congestive Heart Failure in Subjects With Acute Coronary Syndrome | Q34104578 | ||
| PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation | Q34106947 | ||
| Production of the long pentraxin PTX3 in advanced atherosclerotic plaques | Q34128059 | ||
| Anti-inflammatory therapies for cardiovascular disease | Q34137872 | ||
| Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study | Q34150807 | ||
| Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies | Q34154838 | ||
| Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response | Q34159058 | ||
| Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells | Q34180480 | ||
| Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. | Q34184675 | ||
| Emerging role of high density lipoproteins as a player in the immune system. | Q34202968 | ||
| Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility | Q34403569 | ||
| Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation | Q34420055 | ||
| Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension | Q34430183 | ||
| Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. | Q34450228 | ||
| The inflammatory response in myocardial infarction | Q34463456 | ||
| Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism. | Q34549800 | ||
| Long pentraxin PTX3 exacerbates pressure overload-induced left ventricular dysfunction | Q34570880 | ||
| Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. | Q34713240 | ||
| Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes | Q34751855 | ||
| Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia. | Q35021428 | ||
| Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction | Q35026270 | ||
| Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial | Q35140370 | ||
| Associations between pentraxin 3 and severity of coronary artery disease | Q35332533 | ||
| Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress | Q35422363 | ||
| The Therapeutic Potential of the Humoral Pattern Recognition Molecule PTX3 in Chronic Lung Infection Caused by Pseudomonas aeruginosa | Q56942421 | ||
| Role of complement and Fc receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus | Q56942510 | ||
| Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis | Q56942567 | ||
| Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction | Q56942653 | ||
| Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice | Q56942821 | ||
| Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation | Q56942879 | ||
| Pentraxin 3 – A Link Between Obesity, Inflammation and Vascular Disease? – | Q58420640 | ||
| Prognostic value of pentraxin 3 in patients with chronic heart failure | Q80111779 | ||
| Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis | Q82691213 | ||
| Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility? | Q82792256 | ||
| PTX3 is located at the membrane of late apoptotic macrophages and mediates the phagocytosis of macrophages | Q82984348 | ||
| The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells | Q83343192 | ||
| Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction | Q83395035 | ||
| Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability | Q84370651 | ||
| Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques | Q84564232 | ||
| Diagnosis and assessment of Takayasu arteritis by multiple biomarkers | Q85276189 | ||
| Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction | Q85348046 | ||
| Deficiency of Long Pentraxin PTX3 Promoted Neointimal Hyperplasia after Vascular Injury | Q85849383 | ||
| The impact of obesity on pentraxin 3 and inflammatory milieu to acute aerobic exercise | Q86172336 | ||
| Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein | Q87449691 | ||
| The role of pentraxin 3 as diagnostic value in classification of patients with heart failure | Q44694286 | ||
| Correlation between inflammatory markers of atherosclerosis and carotid intima-media thickness in Obstructive Sleep Apnea. | Q44747950 | ||
| Association of pentraxin 3 with insulin resistance and glucose response following maximal aerobic exercise in obese and normal-mass individuals. | Q45033377 | ||
| Pentraxin-3 as a marker of disease activity in Takayasu arteritis | Q45208023 | ||
| Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients | Q45223306 | ||
| Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population | Q45356825 | ||
| PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. | Q45853741 | ||
| Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations | Q46071688 | ||
| Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss | Q46237239 | ||
| Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. | Q46525885 | ||
| Antiviral activity of the long chain pentraxin PTX3 against influenza viruses | Q46739811 | ||
| Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure | Q46830527 | ||
| Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris | Q46927817 | ||
| Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound | Q47760062 | ||
| Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation | Q47941184 | ||
| Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction | Q48395268 | ||
| Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials | Q48458509 | ||
| Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention | Q48482827 | ||
| Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. | Q48770462 | ||
| PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion | Q48786237 | ||
| Increases of pentraxin 3 plasma levels in patients with Parkinson's disease | Q48875364 | ||
| Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. | Q48895262 | ||
| Mesenchymal Stromal Cell-Derived PTX3 Promotes Wound Healing via Fibrin Remodeling | Q50235278 | ||
| Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors? | Q50654551 | ||
| Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. | Q50953649 | ||
| Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus. | Q51076609 | ||
| Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study. | Q51595971 | ||
| Serum pentraxin 3 levels are negatively associated with carotid intima media thickness in non-obese rheumatoid arthritis patients. | Q51646956 | ||
| Regulation of leukocyte recruitment by the long pentraxin PTX3. | Q51774594 | ||
| Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. | Q51802963 | ||
| Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. | Q52583321 | ||
| Novel serum biomarkers in carotid artery stenosis: useful to identify the vulnerable plaque? | Q53217735 | ||
| Plasma Pentraxin3 Level Is Associated With Plaque Vulnerability Assessed by Optical Coherence Tomography in Patients With Coronary Artery Disease. | Q53242378 | ||
| Serum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behçet's disease and relationship with disease activity. | Q53438702 | ||
| Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3. | Q53476226 | ||
| Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. | Q53502969 | ||
| Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. | Q53510759 | ||
| Elevated pentraxin 3 level at the early stage of exercise training is associated with reduction of arterial stiffness in middle-aged and older adults. | Q53663681 | ||
| Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. | Q53708193 | ||
| Inducible expression of the long pentraxin PTX3 in the central nervous system. | Q54051253 | ||
| Long pentraxin PTX3 attenuates ischemia reperfusion injury in a cardiac transplantation model. | Q54791536 | ||
| Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia | Q56942323 | ||
| PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis | Q56942392 | ||
| Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity | Q39477901 | ||
| Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis | Q40576794 | ||
| Elevated inflammatory markers in preeclamptic pregnancies, but no relation to systemic arterial stiffness | Q40898750 | ||
| Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study | Q41151739 | ||
| Pentraxin 3 Induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway | Q41276392 | ||
| Serum Pentraxin-3 Level in Patients Who Underwent Coronary Angiography and Relationship with Coronary Atherosclerosis | Q41741922 | ||
| Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IκB/NF-κB, in atherosclerotic cell model | Q42416522 | ||
| Gastric bypass-induced weight loss alters obesity-associated patterns of plasma pentraxin-3 and systemic inflammatory markers. | Q42481137 | ||
| Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system | Q42584975 | ||
| Analysis of glial secretome: the long pentraxin PTX3 modulates phagocytic activity of microglia | Q42950897 | ||
| Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome | Q43181277 | ||
| Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia | Q43281120 | ||
| Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome | Q43881033 | ||
| Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo | Q43905775 | ||
| Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schönlein purpura nephritis in children | Q43992427 | ||
| Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals | Q44072391 | ||
| Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients | Q44456570 | ||
| Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction | Q44598096 | ||
| Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica | Q44605195 | ||
| Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease | Q35664554 | ||
| Correlation between pentraxin-3 and endothelial dysfunction in obstructive sleep apnea syndrome | Q35898602 | ||
| Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis | Q35900660 | ||
| Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response | Q35915482 | ||
| Inflammation in atherosclerosis | Q36174933 | ||
| The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps | Q36209095 | ||
| The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps | Q36229261 | ||
| Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure | Q36249503 | ||
| Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease | Q36656294 | ||
| Promoter Structure and Transcriptional Activation of the Murine TSG-14 Gene Encoding a Tumor Necrosis Factor/Interleukin-1-inducible Pentraxin Protein | Q36685346 | ||
| Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease | Q36736700 | ||
| Astrocyte-Derived Pentraxin 3 Supports Blood-Brain Barrier Integrity Under Acute Phase of Stroke | Q36739655 | ||
| Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases | Q36830914 | ||
| Role of the soluble pattern recognition receptor PTX3 in vascular biology | Q36924394 | ||
| C-reactive protein, fibrinogen, and cardiovascular disease prediction | Q37021409 | ||
| Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria | Q37123175 | ||
| Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study | Q37141153 | ||
| The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice | Q37164532 | ||
| Pentraxins, humoral innate immunity and tissue injury | Q37200012 | ||
| Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome | Q37309372 | ||
| Regulation of pentraxin-3 by antioxidants | Q37422565 | ||
| The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury | Q37627769 | ||
| The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention. | Q37668815 | ||
| Rolling back neutrophil adhesion | Q37714320 | ||
| The Potential Role of Aerobic Exercise-Induced Pentraxin 3 on Obesity-Related Inflammation and Metabolic Dysregulation | Q37733630 | ||
| Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications | Q37944361 | ||
| Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis | Q38259145 | ||
| Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. | Q38322573 | ||
| Biological actions of pentraxins | Q38472979 | ||
| Targeting Inflammation in Primary Cardiovascular Prevention | Q38934217 | ||
| Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome. | Q38935475 | ||
| The Role of Inflammation in Cardiovascular Outcome. | Q39134471 | ||
| Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease. | Q39252622 | ||
| P921 | main subject | atherosclerosis | Q12252367 |
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 1-12 | |
| P577 | publication date | 2017-10-16 | |
| P1433 | published in | Vascular Pharmacology | Q7916446 |
| P1476 | title | Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases | |
| P478 | volume | 99 |
| Q48317284 | A critical role of pentraxin 3 in severe sepsis and septic shock |
| Q89834282 | Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction |
| Q64988205 | Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril. |
| Q97526121 | Elevated Levels of Pentraxin 3 Correlate With Neutrophilia and Coronary Artery Dilation During Acute Kawasaki Disease |
| Q90117015 | Increased Expression of Pentraxin 3 in Placental Tissues from Patients with Unexplained Recurrent Pregnancy Loss |
| Q89477733 | Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease |
| Q91970155 | Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality |
| Q57300029 | Pathogenicity Induced by Invasive Infection of subsp. in a Mouse Model of Diabetes |
| Q98613703 | The Effect of Nano-Curcumin Supplementation on Pentraxin 3 Gene Expression and Serum Level in Migraine Patients |
Search more.